Spectrum of tardive syndromes: Clinical recognition and management

Postgraduate Medical Journal

Volumn 87, Issue 1024, 2011, Pages 132-141

  Bhidayasiri, Roongroj ^a,b   Boonyawairoj, Suthida ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DIBENZAZEPINE DERIVATIVE; DIPHENYLBUTYLPIPERIDINE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; DROPERIDOL; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; PERPHENAZINE; PHENOTHIAZINE DERIVATIVE; PIMOZIDE; PROCHLORPERAZINE; QUETIAPINE; SULPIRIDE; THIORIDAZINE; THIOXANTHENE DERIVATIVE; TIAPRIDE; TIOTIXENE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; UNINDEXED DRUG;

AGING; AKATHISIA; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSTONIA; HUMAN; MOTOR DYSFUNCTION; PALLIDOTOMY; REVIEW; RISK FACTOR; STEREOTAXIC SURGERY; TARDIVE DYSKINESIA;

HUMANS; MOVEMENT DISORDERS; RISK FACTORS; SYNDROME;

EID: 79951551292     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2010.103234     Document Type: Review

References (98)

1. Schonecker M. [Paroxysmal dyskinesia as the effect of megaphen]. Nervenarzt 1957;28:550-3.
2. Baldessarini RJ, Cole JO, Davis JM, et al. Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. Am J Psychiatry 1980;137:1163-72. (Pubitemid 10015060)
3. Dyskinesia APATFoT. Tardive Dyskinesia-A Task Force Report of the American Psychiatric Association. Washington DC: American Psychiatric Press, 1992.
4. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995;18:197-214.
5. Fernandez HH, Friedman JH. Classification and treatment of tardive syndromes. Neurologists 2003;9:16-27. (Pubitemid 36164020)
6. Woerner MG, Kane JM, Lieberman JA, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991;11:34-42.
7. Yassa R, Nair NP. A 10-year follow-up study of tardive dyskinesia. Acta Psychiatr Scand 1992;86:262-6.
8. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473-81.
9. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992;18:701-15.
10. Orti-Pareja M, Jimenez-Jimenez FJ, Vazquez A, et al. Drug-induced tardive syndromes. Parkinsonism Relat Disord 1999;5:59-65. (Pubitemid 29256369)
11. Yassa R, Nair V, Dimitry R. Prevalence of tardive dystonia. Acta Psychiatr Scand 1986;73:629-33. (Pubitemid 16100683)
12. Jeste DV, Wyatt RJ. Changing epidemiology of tardive dyskinesia: An overview. Am J Psychiatry 1981;138:297-309. (Pubitemid 11155876)
13. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005;50:703-14. (Pubitemid 43175488)
14. Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 2004;65(Suppl 9):21-4.
15. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004;65(Suppl 9):16-20.
16. Shedlack KJ, Soldato-Couture C, Swanson CL Jr. Rapidly progressive tardive dyskinesia in AIDS. Biol Psychiatry 1994;35:147-8. (Pubitemid 24084134)
17. Barnes TR. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia. Psychiatr Dev 1987;5:301-19. (Pubitemid 18071624)
18. Simpson GM, Lee JH, Zoubok B, et al. A rating scale for tardive dyskinesia. Psychopharmacology 1979;64:171-9. (Pubitemid 9227085)
19. Stacy M, Jankovic J. Tardive dyskinesia. Curr Opin Neurol Neurosurg 1991;4:343-9.
20. Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology 1993;43:937-41. (Pubitemid 23150565)
21. Miller LG, Jankovic J. Neurologic approach to drug induced movement disorders in 125 patients. South Med J 1990;83:525-32. (Pubitemid 20174511)
22. Jankovic J. Stereotypies. In: Marsden CD FS, ed. Movement disorder 3. London: Butterworth-Heinemann, 1994:503-17.
23. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982;32:1335-46. (Pubitemid 13203738)
24. Bhidayasiri R, Bronstein JM. Improvement of cervical dystonia: possible role of transcranial magnetic stimulation simulating sensory tricks effect. Med Hypotheses 2005;64:941-5. (Pubitemid 40385948)
25. Kiriakakis V, Bhatia KP, Quinn NP, et al. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 1998;121(Pt 11):2053-66.
26. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986;1:193-208.
27. Burke RE, Kang UJ, Jankovic J, et al. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989;4:157-75. (Pubitemid 19128939)
28. Hansen L, Jones RM, Kingdon D. No association between akathisia or Parkinsonism and suicidality in treatment-resistant Schizophrenia. J Psychopharmacol 2004;18:384-7. (Pubitemid 39382566)
29. Tominaga H, Fukuzako H, Izumi K, et al. Tardive myoclonus. Lancet 1987;1:322. (Pubitemid 17009801)
30. Stacy M, Jankovic J. Tardive tremor. Mov Disord 1992;7:53-7.
31. Marsalek M. Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000;33(Suppl 1):14-33.
32. Hyde TM, Hotson JR, Kleinman JE. Differential diagnosis of choreiform tardive dyskinesia. J Neuropsychiatry Clin Neurosci 1991;3:255-68.
33. Bhidayasiri R, Truong DD. Chorea and related disorders. Postgrad Med J 2004;80:527-34. (Pubitemid 39265296)
34. Stober T, Wussow W, Schimrigk K. Bicaudate diameter - the most specific and simple CT parameter in the diagnosis of Huntington's disease. Neuroradiology 1984;26:25-8. (Pubitemid 14211882)
35. McCreadie RG, Thara R, Padmavati R, et al. Structural brain differences between never-treated patients with schizophrenia, with and without dyskinesia, and normal control subjects: a magnetic resonance imaging study. Arch Gen Psychiatry 2002;59:332-6. (Pubitemid 34275251)
36. El-Youssef M. Wilson disease. Mayo Clin Proc 2003;78:1126-36. (Pubitemid 37055657)
37. La Fontaine S, Mercer JF. Trafficking of the copper-ATPases, ATP7A and ATP7B: role in copper homeostasis. Arch Biochem Biophys 2007;463:149-67.
38. Tao TY, Liu F, Klomp L, et al. The copper toxicosis gene product Murr1 directly interacts with the Wilson disease protein. J Biol Chem 2003;278:41593-6. (Pubitemid 37310414)
39. Winsberg BG, Hurwic MJ, Perel J. Neurochemistry of withdrawal emergent symptoms in children. Psychopharmacol Bull 1977;13:38-40.
40. Weiner WJ, Klawans HL Jr. Lingual-facial-buccal movements in the elderly. I. Pathophysiology and treatment. J Am Geriatr Soc 1973;21:314-17.
41. Lauterbach EC, Shillcutt SD. Dyskinesia with fluoxetine: tardive or late-onset persistent, acute norfluoxetine dyskinesia? J Clin Psychiatry 1997;58:85-6.
42. Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-89; quiz 523.
43. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005;20(Suppl 11):S11-16.
44. Vidailhet M, Bonnet AM, Marconi R, et al. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 1999;14(Suppl 1):13-18. (Pubitemid 29509469)
45. Bhidayasiri R, Truong DD. Motor complications in Parkinson disease: clinical manifestations and management. J Neurol Sci 2008;266:204-15. (Pubitemid 351186508)
46. Koller WC. Edentulous orodyskinesia. Ann Neurol 1983;13:97-9. (Pubitemid 13224208)
47. Blanchet PJ, Popovici R, Guitard F, et al. Pain and denture condition in edentulous orodyskinesia: comparisons with tardive dyskinesia and control subjects. Mov Disord 2008;23:1837-42.
48. Chou KL, Friedman JH. Tardive syndromes in the elderly. Clin Geriatr Med 2006;22:915-33, viii.
49. Saltz BL, Kane JM, Woerner MG, et al. Prospective study of tardive dyskinesia in the elderly. Psychopharmacol Bull 1989;25:52-6. (Pubitemid 19179160)
50. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8(4 Suppl):52S-6S.
51. Gardos G, Cole JO, Rapkin RM, et al. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Arch Gen Psychiatry 1984;41:1030-5.
52. Eberhard J, Lindstrom E, Levander S. Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course. Int Clin Psychopharmacol 2006;21:35-42. (Pubitemid 43175121)
53. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 2005;50:541-7. (Pubitemid 43161786)
54. Silvestri S, Seeman MV, Negrete JC, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000;152:174-80.
55. Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993;34:713-38. (Pubitemid 23354784)
56. Sachdev PS. The current status of tardive dyskinesia. Aust N Z J Psychiatry 2000;34:355-69. (Pubitemid 30389406)
57. Glazer WM, Morgenstern H, Schooler N, et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry 1990;157:585-92. (Pubitemid 20335972)
58. Dalack GW, Becks L, Meador-Woodruff JH. Tardive dyskinesia, clozapine, and treatment response. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:567-73. (Pubitemid 28281223)
59. Modestin J, Stephan PL, Erni T, et al. Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr Res 2000;42:223-30. (Pubitemid 30216533)
60. Bassitt DP, Louza Neto MR. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1998;248:209-11. (Pubitemid 28468502)
61. Vesely C, Kufferle B, Brucke T, et al. Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine. Int Clin Psychopharmacol 2000;15:57-60. (Pubitemid 30058142)
62. Soutullo CA, Keck PE Jr, McElroy SL. Olanzapine in the treatment of tardive dyskinesia: a report of two cases. J Clin Psychopharmacol 1999;19:100-1. (Pubitemid 29047340)
63. Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54:327-30.
64. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15(1 Suppl 1):36S-44S.
65. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997;12:483-96. (Pubitemid 27322876)
66. Simpson GM, Lee JH, Shrivastava RK. Clozapine in tardive dyskinesia. Psychopharmacology (Berl) 1978;56:75-80. (Pubitemid 8270659)
67. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-10.
68. Small JG, Milstein V, Marhenke JD, et al. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 1987;48:263-7. (Pubitemid 17108402)
69. Meltzer HY, Luchins DJ. Effect of clozapine in severe tardive dyskinesia: a case report. J Clin Psychopharmacol 1984;4:286-7. (Pubitemid 14013152)
70. Van Putten T, Wirshing WC, Marder SR. Tardive Meige syndrome responsive to clozapine. J Clin Psychopharmacol 1990;10:381-2. (Pubitemid 20378691)
71. Trugman JM, Leadbetter R, Zalis ME, et al. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Mov Disord 1994;9:441-6. (Pubitemid 24238373)
72. Simpson GM. The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatry 2000;61(Suppl 4):39-44. (Pubitemid 30158602)
73. Soares KV, McGrath JJ. The treatment of tardive dyskinesia - a systematic review and meta-analysis. Schizophr Res 1999;39:1-16; discussion 7-8.
74. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997;23:583-609. (Pubitemid 27485969)
75. Bhidayasiri R, Tarsy D. Treatment of dystonia. Expert Rev Neurother 2006;6:863-86. (Pubitemid 43961888)
76. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156:1279-81. (Pubitemid 29374894)
77. Lieberman J, Pollack S, Lesser M, et al. Pharmacologic characterization of tardive dyskinesia. J Clin Psychopharmacol 1988;8:254-60.
78. Yagi G, Takamiya M, Kanba S, et al. Mortality rate of schizophrenic patients with tardive dyskinesia during 10 years: a controlled study. Keio J Med 1989;38:70-2.
79. Izumi K, Tominaga H, Koja T, et al. Meclofenoxate therapy in tardive dyskinesia: a preliminary report. Biol Psychiatry 1986;21:151-60. (Pubitemid 16040343)
80. Bergman J, Dwolatzky T, Brettholz I, et al. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders. J Clin Psychiatry 2005;66:107-10.
81. Caroff SN, Campbell EC, Havey JC, et al. Treatment of tardive dyskinesia with donepezil. J Clin Psychiatry 2001;62:128-9.
82. Schopick D. Donepezil and tardive dyskinesia. J Am Acad Child Adolesc Psychiatry 2005;44:112.
83. Soares KV, McGrath JJ, Deeks JJ. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001;(2):CD000203.
84. Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 1990;147:445-51. (Pubitemid 20107108)
85. Singh MM, Becker RE, Pitman RK, et al. Sustained improvement in tardive dyskinesia with diazepam: indirect evidence for corticolimbic involvement. Brain Res Bull 1983;11:179-85. (Pubitemid 13016839)
86. Stewart RM, Rollins J, Beckham B, et al. Baclofen in tardive dyskinesia patients maintained on neuroleptics. Clin Neuropharmacol 1982;5:365-73. (Pubitemid 13189078)
87. Gerlach J, Rye T, Kristjansen P. Effect of baclofen on tardive dyskinesia. Psychopharmacology (Berl) 1978;56:145-51. (Pubitemid 8287697)
88. Brashear A, Ambrosius WT, Eckert GJ, et al. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord 1998;13:158-61. (Pubitemid 28029869)
89. Tarsy D, Kaufman D, Sethi KD, et al. An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 1997;20:90-3. (Pubitemid 27098361)
90. Chatterjee A, Forrest Gordon M, Giladi N, et al. Botulinum toxin in the treatment of tardive dystonia. J Clin Psychopharmacol 1997;17:497-8. (Pubitemid 28389197)
91. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-94.
92. Egan MF, Hyde TM, Albers GW, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992;149:773-7.
93. Adler LA, Peselow E, Rotrosen J, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993;150:1405-7. (Pubitemid 23259578)
94. Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry 1999;56:836-41. (Pubitemid 29420705)
95. Gruber D, Trottenberg T, Kivi A, et al. Long-term effects of pallidal deep brain stimulation in tardive dystonia. Neurology 2009;73:53-8.
96. Trottenberg T, Volkmann J, Deuschl G, et al. Treatment of severe tardive dystonia with pallidal deep brain stimulation. Neurology 2005;64:344-6.
97. Eltahawy HA, Feinstein A, Khan F, et al. Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. Mov Disord 2004;19:969-72. (Pubitemid 39199270)
98. Damier P, Thobois S, Witjas T, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry 2007;64:170-6. (Pubitemid 46220774)